Advertisement
 
YOU ARE HERE: LAT HomeCollectionsEpogen
IN THE NEWS

Epogen

BUSINESS
March 28, 2000 |
Shares of Amgen Inc. rose 9% Monday as the world's biggest biotechnology company went to court for preliminary hearings on its bid to keep rival Transkaryotic Therapies Inc. from introducing a version of Amgen's blockbuster anemia drug Epogen in the U.S. Amgen shares rose $5.81 to close at $60.38 on the Nasdaq Stock Market. Transkaryotic shares fell $7.88, or 10%, to close at $70.25, also on Nasdaq. At stake is one of the world's top-selling medicines.
Advertisement
CALIFORNIA | LOCAL
March 14, 2000 | BARBARA MURPHY
Amgen Inc., the world's largest biotechnology company, has raised the price of its anemia drug Epogen for the first time in the drug's 11-year history. Amgen spokesman Peter Teeley said the price of Epogen, the company's best-selling product, will rise 3.9% because inflation is increasing its costs. The price rise may be a sign Amgen needs to boost profit because it plans to increase spending to introduce new products, an analyst said.
CALIFORNIA | LOCAL
February 8, 2000
Amgen earnings rose 18% during the fourth quarter, capping a year of record growth for the Thousand Oaks biotech company and beating Wall Street's expectations by a penny a share. Amgen reported that it earned $282 million, or 26 cents per share, up from $239 million, or 22 cents per share, during the fourth quarter of 1998. Sales increased 22% during the quarter to $847 million. On the year, Amgen's earnings rose 27% to $1.1 billion or $1.
CALIFORNIA | LOCAL
November 16, 1999 | BARBARA MURPHY
The U.S. Food and Drug Administration has approved the Amgen drug Epogen for the treatment of anemia in children with chronic kidney failure who are undergoing dialysis therapy. Epogen elevates or maintains the red blood cell level and virtually eliminates the need for blood transfusions in patients. The FDA's action came almost on the 10th anniversary of Epogen's initial approval for use with adults.
CALIFORNIA | LOCAL
October 12, 1999 | BARBARA MURPHY
Amgen has dedicated a manufacturing facility in Longmont, Colo., which initially will produce Epoetin alfa, a protein marketed in the United States under the name Epogen. The drug is used to treat dialysis patients who suffer from anemia associated with kidney failure. Amgen officials said the Longmont plant eventually will produce other drugs as well.
CALIFORNIA | LOCAL
October 5, 1999 | BARBARA MURPHY
Amgen Inc.'s NESP, an extended-release version of its blockbuster anemia drug Epogen, is as effective as the original, according to a research summary to be presented in November. A study of 522 patients on kidney dialysis found that those given NESP once a week or once every two weeks fared as well as those given Epogen once a week to three times a week. The side effects, deaths and withdrawals from the study were the same in both groups.
BUSINESS
July 27, 1999 | From Bloomberg News
Amgen Inc. said court proceedings will resume in April 2000 in a patent dispute with fledgling biotech company Transkaryotic Therapies Inc. over Amgen's top-selling anemia drug erythropoietin. The battle pits Amgen, the world's No. 1 biotechnology company based in Thousand Oaks, against Transkaryotic, a money-losing biotech company based in Cambridge, Mass., and its development partner, No. 1 German drugmaker Hoechst AG.
CALIFORNIA | LOCAL
May 4, 1999
Biotech giant Amgen in Thousand Oaks said first-quarter earnings rose 32% as sales of its blockbuster anemia drug Epogen soared. Net income rose to $247 million or 46 cents a share, up from $187 million or 35 cents a year earlier. The results exceeded the 44-cent average estimate of analysts surveyed by First Call Corp. Revenue rose 23% to $745.4 million from $605.4 million, led by a 30% increase in sales of Epogen, which reached $395 million.
BUSINESS
February 2, 1999 | James Peltz and Michael Hiltzik
Stock Exchange gives readers a chance to listen in as staff writers James Peltz and Michael Hiltzik debate the merits of individual stocks and other investments. Amgen (AMGN) Jim: Mike, our stock today is Amgen, the giant biotechnology company based in Thousand Oaks, and what a success story this outfit is. If there's a stock I think everyone wishes they had bought a few years ago, in addition to Microsoft, it might be Amgen.
BUSINESS
January 29, 1999 | From Bloomberg News
Amgen Inc., the world's largest biotechnology company, said Thursday that its fourth-quarter earnings rose 33%, beating analysts' estimates, as sales of its blockbuster anemia drug Epogen soared. Net income for the period ended Dec. 31 rose to $239 million, or 90 cents a share, from $180 million, or 67 cents, a year earlier. Results beat the 84-cent average estimate of analysts surveyed by First Call Corp. Epogen sales rose 35% to $391 million from $289 million a year earlier.
Los Angeles Times Articles
|